SSSS vs ELTX Comparison

SuRo Capital Corp is a non-diversified closed-end management investment company. The Company's investment objective is to maximize total return, mainly through capital gains on equity and equity-related investments, and to a lesser extent, income from debt investments. It invests mainly in equity securities of rapidly growing, venture capital-backed emerging companies. Investments are made through direct investments, secondary marketplaces, negotiations with selling stockholders, and investment funds or special purpose vehicles (SPVs). The Company may also invest in private credit, founder equity and warrants, and private investment in public equity (PIPE) transactions of special purpose acquisition companies (SPACs).

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.